Athenex, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 280
- Market Cap
- -
- Website
- http://www.athenex.com
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02250157
- Locations
- ๐บ๐ธ
University of Colorado Cancer Center, Aurora, Colorado, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01074138
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐บ๐ธWayne State University-Karmanos Cancer Center, Detroit, Michigan, United States
Evaluation of KX2-391 in Patients With Advanced Malignancies
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00658970
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath